Friday, January 6, 2012

South Africa's ANC party celebrates 100 years

File-In this Aug. 2 2008 file photo, former South African President Nelson Mandela, flanked by African President Thabo Mbeki, right, and ANC President Jacob Zuma, left, cuts a birthday cake at the Loftus Versfeld stadium in Pretoria, South Africa for a celebration of Mandela's 90th birthday, organized by the African National Congress. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012.(AP Photo/Jerome Delay, file)

File-In this Aug. 2 2008 file photo, former South African President Nelson Mandela, flanked by African President Thabo Mbeki, right, and ANC President Jacob Zuma, left, cuts a birthday cake at the Loftus Versfeld stadium in Pretoria, South Africa for a celebration of Mandela's 90th birthday, organized by the African National Congress. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012.(AP Photo/Jerome Delay, file)

FILE - This April 27, 1994 aerial file photo shows long lines of people queuing outside the polling station in the black township of Soweto, in the southwest suburbs of Johannesburg, South Africa. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012.The majority of South Africa's 22 million voters were voting in the nation's first all-race elections. (AP Photo/Denis Farrell, File)

FILE- In this March 28 1960 file photo, members of the African National Congress take part in a day of mourning at Orlando East, near Johannesburg, South Africa. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012. Building in background has words "away with Verwoerd" painted on it. Verwoerd was South Africa's Prime Minister and strong proponent of the racial policies which led to the mass shooting at Sharpesville. (AP Photo/file)

FILE - In this Sunday Feb. 11, 1990 file photo, Nelson Mandela and his then wife Winnie, walk hand in hand upon his release from Victor prison, Cape Town, South Africa. The African National Congress leader had served over 27 years in detention. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012. (AP Photo/File)

FILE -in this Sept. 15 1990 file photo, The burning body of a man identified as a Zulu Inkatha supporter is clubbed by followers of the rival African National Congress during factional violence in Soweto, South Africa. Against all odds, the party of Nelson Mandela which has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only, is celebrating its 100th anniversary in Bloemfontein Sunday Jan 8 2012.(AP Photo/Greg Marinovich, File)

(AP) ? Against all odds, the party of Nelson Mandela has transformed a nation where just 20 years ago black South Africans could not vote, and beaches and restaurants were reserved for whites only.

The venerated party once banned for decades under apartheid has won every national election since racist white rule ended in 1994, and President Jacob Zuma vows the party "will rule until Jesus comes."

Yet as the African National Congress marks its 100th anniversary this weekend with fanfare and dozens of visiting presidents, critics say the ANC has failed to unchain an impoverished majority still shackled by a white-dominated economy.

Unemployment hovers around 36 percent and soars to 70 percent among young people. Half of the country's population lives on just 8 percent of the national income, according to the Congress of South African Trade Unions.

South African political analyst Aubrey Matshiqi praises the ANC for developmental achievements "unprecedented anywhere in the world" in its 17 years of governing the country.

But he noted that many at the ANC festivities will have their joy marred by "a tinge of disappointment and even sadness" about weaknesses and failures.

The ANC's reputation is being tarnished by a never-ending deluge of corruption scandals, some involving politicians who sacrificed during the fight against apartheid and now feel entitled to luxury cars and financial payback.

It's created disillusionment, especially for those who volunteered to serve as freedom fighters at a time when many of the ANC's leaders were imprisoned for their activism.

Serame Mogale, who was only 14 when he became a guerrilla fighter for the ANC, recalled that the slogan in one Angolan training camp was "the pace of the slowest."

"We would run six hours nonstop with female comrades in front, from whom the whole company or platoon will take the pace," he recalls. "But today, the weakest is overtaken and left behind to tire and die."

Africa's oldest liberation movement is kicking off the festivities with a golf tournament ? an event critics say shows how the grassroots-based movement has morphed into an elitist-run political party.

More than 100,000 people are expected for the ANC centenary festivities, including 46 heads of state and a dozen former presidents, the party says. Nobel peace laureate Desmond Tutu is coming, though it's unclear whether Mandela will make an appearance.

The 93-year-old icon's public appearances have become increasingly rare, though he did attend the closing ceremony of the World Cup in 2010. He also made a surprise appearance at a campaign rally ahead of the 2009 election, when the ANC faced unprecedented competition from a breakaway party.

"I would be nothing without the ANC," Mandela said at a 2008 party rally marking his 90th birthday.

The political party representing South Africa's impoverished majority already has drawn criticism for spending 10 million rand (nearly $1.5 million) of public money to buy the church where it all began.

The Wesleyan church is the focus of this weekend's centenary celebrations in Bloemfontein, a city in the heart of the country. It was here that black activists and intellectuals founded the liberation movement that would help lead the decades-long struggle against racist rule.

Until just 20 years ago, blacks were evicted from their homes and herded into separate suburbs, forced to work under slave-like conditions on mines and farms. Families were separated under legalized race discrimination so that white entrepreneurs could take advantage of poorly paid black laborers.

The best parks, beaches and restaurants were reserved for the white minority, with signs in Afrikaans saying "Nie Blankies" ? Whites Only. Some shops would only serve blacks through a hole in the wall.

Black nannies cared for white children and prepared elaborate meals for white families, then went to hovels in the backyards of mansions to feed their own children "ration meat" ? bones and fat less nutritious than the meals served to white families' dogs.

A turning point came in 1960, police turned their guns on about 300 people peacefully protesting "pass laws" restricting them to certain areas and requiring them to leave white areas where they worked by nightfall.

At least 69 people were killed and scores wounded in the Sharpeville massacre. The unprovoked slaughter attracted international condemnation that formed the roots of the global anti-apartheid movement.

The government declared a state of emergency and banned South Africa's two liberation movements ? the Pan Africanist Congress, which had organized the Sharpeville protest, and the ANC.

ANC leaders declared there was no longer any space to organize nonviolent resistance and formed Umkhonto we Sizwe, Zulu for "Spear of the Nation," an army that would wage a guerrilla war for liberation.

"The time comes in the life of any nation when there remain only two choices: submit or fight. That time has now come to South Africa. We shall not submit but we shall fight back by all our means within our power for the liberation of our motherland," said the guerrilla army manifesto.

After Mandela's 1990 release from prison, he was elected president of ANC and went on to become South Africa's first black president after the historic 1994 election.

While the ANC confronted a common enemy in apartheid, it became a catchall for people of many different ideological persuasions. Once the enemy was defeated, it is not surprising that differences have arisen.

"We would like to think it (the ANC) has teething problems, but it's not really only teething problems," says Amina Cachalia, a political activist who joined the ANC in the 1940s. "I think suddenly it's become a different platform for different ideologies and for different people with different agendas, and that's a pity, a great pity."

The party also has struggled to find a leader as charismatic as the beloved anti-apartheid icon.

Thabo Mbeki, the president who succeeded Mandela, was unceremoniously booted out of office by an ANC congress that deemed him too cerebral and out of touch with the people.

Today the ANC is led by Zuma, a guerrilla fighter who was imprisoned at Robben Island alongside Mandela but whose polygamous lifestyle and extramarital affairs have scandalized South Africans.

Zuma's leadership is being challenged by Julius Malema, the very same fiery youth leader credited with ousting Mbeki and helping bring Zuma to power in 2007. Late last year, an ANC disciplinary committee fired Malema and suspended him from the party for five years.

Malema, who is awaiting the result of an appeal and is under police investigation for corruption and tax evasion, has been denied the opportunity to address the centenary celebrants. But he will speak at smaller rallies near Bloemfontein, the party said of the young firebrand who draws support from young adults.

Sifiso Mkwanazi, a 26-year-old self-employed businessman, complains about the government's lack of investment to create jobs and better education opportunities.

"For the generation of my parents, I think it (the ANC) has done a lot, but with our generation, I don't think they are contributing as much as they should be," he says.

Still, he said his vote would go to the ANC unless a viable opposition party devoted to the people's interest springs up.

Cachalia, who has been a friend of Mandela for 60 years, says she wonders what he would make of the ANC's evolution.

"I sometimes feel very disillusioned these days, but I suppose we live in hope," she says.

___

Associated Press writers Ed Brown and Krista Larson contributed to this report from Johannesburg.

___

Online:

African National Congress: http://www.anc.org.za

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/cae69a7523db45408eeb2b3a98c0c9c5/Article_2012-01-05-AF-South-Africa-ANC-at-100/id-9c18161b9d8741b88d59b0064c1efcb2

whitney cummings larry the cable guy

Sky Sports Pundit: Wasteful Liverpool Forwards 'Need to Chip in'

Luis Suarez is Liverpool's top-scorer with eight goals. REUTERS

Luis Suarez is Liverpool's top-scorer with eight goals. REUTERS

Jamie Redknapp has challenged Liverpool's profligate strike force to assume greater responsibility after the club announced it would not appeal against Luis Suarez's ban.

Liverpool decided not to challenge the FA's decision to ban Suarez for eight-games for racially abusing Manchester United's Patrice Evra, but issued a strongly worded statement that attempted to recast the Uruguayan as the innocent victim in the case.

Suarez served the first match of his ban in Tuesday's 3-0 defeat at Manchester City; the sixth time Kenny Dalglish's side have failed to score this season.

And Redknapp believes it is now up to Andy Carroll, Dirk Kuyt, Craig Bellamy and Stewart Downing - who have scored six goals of Liverpool's 24 goals this season - to fill the void left by Suarez's absence.

Like us on Facebook

"They've now got to produce performances," Redknapp told Sky Sports.

"It's alright playing somebody, but they've got to want to do it and they've got to do it. Against City we saw the first glimpse without Luis Suarez and at times it was difficult.

"Away from home of late, Liverpool have looked very good. Suarez gives them something completely different, he is a wonderful footballer.

"Without him you've got Carroll up front and at times they get caught between playing long, trying to play up to him and using his aerial ability."

Kenny Dalglish's side have scored just 24 times in 19 Premier League games this season and the Liverpool boss has been linked with a number of transfer targets in the January window.

However, Redknapp believes Dalglish's squad is strong enough to cope in the Uruguayan's absence and has backed Bellamy to tempt the best form from their ?35m-signing.

"They struggled at times against City and that's why I think Bellamy may play up front, then they can play quicker passing football. Carroll, at the moment, is not in the best form.

"Kenny talks about having players that are clinical, but they haven't got that. Downing's not scoring, Kuyt's not scoring goals.

"Players now need to chip in and start scoring some goals."

To report problems or to leave feedback about this article, e-mail:
To contact the editor, e-mail:

Source: http://www.ibtimes.com/articles/276181/20120104/sky-sports-pundit-wasteful-liverpool-forwards-need.htm

les miles beyonce dance for you video beyonce dance for you video

Thursday, January 5, 2012

This New Steve Jobs Action Figure Is So Good It's Freaky [Steve Jobs]

This is not the first Steve Jobs, but it's definitely the most realistic. So realistic that it actually freaks me out. It's 12 inches high (scale 1:6) and comes on full Apple CEO regalia, from the New Balance to the Levi's. More »


Source: http://feeds.gawker.com/~r/gizmodo/full/~3/L_7vqndFJ7Y/this-new-steve-jobs-action-figure-is-so-good-its-freaky

andrew bynum anderson cooper rodney atkins diplo

Wednesday, January 4, 2012

User agents, Email sync [From the Forums]

From the Forums

Tablets, bootloaders, ICS -- Oh, my. Even though it's only Tuesday, this week appears to be flying by with all the news that is happening. If you missed out on anything thus far, jump back a page and get yourself caught up or, make your presence known in the Android Central forums where you can find plenty of help, tips and tricks and much more:

If you're not already a member of the Android Central forums, you can register your account today.



Source: http://feedproxy.google.com/~r/androidcentral/~3/C_B8hvFI1cE/story01.htm

plane crash

Analysis: New Teva CEO to shift focus to branded drugs (Reuters)

JERUSALEM (Reuters) ? Teva Pharmaceutical Industries' new chief executive is set to shift the company's focus to branded drugs from generics as he imports a successful strategy of making mid-sized deals from Bristol-Myers Squibb.

The transformation -- which hinges on Jeremy Levin picking a handful of winning new products to boost Teva's branded portfolio -- is unlikely to happen overnight.

In hunting for potentially lucrative experimental medicines, Levin will be competing with a wide field of rivals, including the world's biggest pharmaceutical manufacturers, most of whom are hungry for new drugs to refill pipelines depleted by patent expirations.

Levin, senior vice president for strategy, alliances and transactions at Bristol-Myers since 2007, will take the reins at Teva in May in the wake of Shlomo Yanai's surprising resignation after five years at the helm.

Teva's shares jumped 3.3 percent on the news on Monday in Tel Aviv, an indication that investors were unhappy with Yanai -- who engineered a number of large acquisitions -- and sought a change in direction that included a strategy to replace its top-selling multiple sclerosis drug Copaxone.

Analysts believe the move to change CEOs had been in the works for months since Teva's share performance has been poor and Teva Chairman Phillip Frost said the process to find a successor to Yanai took almost all of last year and that the transition process should be orderly.

The South African-born, Cambridge-educated Levin, global head of business development and strategic alliances at Novartis from 2003 to 2007, has so far declined to give any specifics on his strategy for Israel-based Teva, citing the need to complete a "deep dive" in the next few months.

But he told analysts on a conference call on Tuesday that there was no difference between generic and proprietary drugs.

"I have a deep philosophy in that medicines are medicines. It does not matter whether they are branded or generic," Levin said. "The key question is can you make the affordable and can you provide them to patients."

Teva's Nasdaq shares were up 6.5 percent at $42.97 on Tuesday, still nearly 40 percent below a year's high of $57.08 on January 26, 2011.

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Teva's sliding price/earnings ratio: http://link.reuters.com/tyb85s

^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

"STRING OF PEARLS"

Many analysts believe Teva's shares could be poised for a rebound after its Nasdaq shares fell 21 percent in 2011 to underperform the drugs sector.

"Levin comes from a Bristol-Myers management team that has substantially turned around the company, has been very shareholder friendly and is very well regarded by (Wall) Street," JPMorgan analyst Chris Schott wrote in a client note.

"Clearly, we will have to watch for any further changes in Teva's strategy as Levin moves into his new role but after a difficult year for Teva shares, we believe the transition will be well received," added Schott, who rates Teva as "overweight" with a $55 price target.

At Bristol-Myers, Levin implemented a "string of pearls" strategy of alliances, partnerships and acquisitions with small and large companies -- a policy he is expected to continue at Teva as it looks for a way that its branded business can grow.

Levin's appointment "clearly signals that Teva will remain acquisitive in building its brand business but at an appropriate scale since Levin will likely attempt to recreate his 'string-of-pearls' success," said Barclays Capital's Douglas Tsao.

As a result, additional large acquisitions that propelled Teva to the world's largest maker of copycat medicines are unlikely, and could prompt the company to back off its ambitious target of $31 billion in sales by 2015.

Teva, which has a market value of $36 billion, is forecast to post sales of $22 billion in 2012, $12 billion coming from generic drugs. Nearly $4 billion is projected from Copaxone, whose sales are forecast to peak this year.

Copaxone, an injected drug, now accounts for 23.5 percent of total sales, compared with 19 percent a year ago and faces competition from a variety of oral MS treatments that are available or are expected to hit the market in the coming years.

Novartis' recently launched drug Gilenya is the first oral MS drug to reach the market while Biogen Idec's experimental drug BG-12, if approved, promises to become a leading treatment for MS. Teva's own experimental MS pill laquinimod missed its main goal in a late-stage trial in what was seen as a major setback.

Analysts also expect fewer generic blockbuster drugs to hit the market starting on 2013 in another hit to Teva.

EMERGING MARKETS FOCUS

Through Cephalon, Teva has about 30 branded drugs in various stages of development and clinical trial and analysts expect Levin to ultimately decide which of them to push more aggressively.

"Teva's success in the branded business remains an open question in the coming years," Jonathan Kreizman, an analyst at the Clal Finance brokerage said, citing the failure of Parkinson's disease drug Azilect. "The generics and branded businesses are very different and Teva will have to prove itself like it did in generics.

"Developing drugs is more risky and different than imitating drugs," he said.

Another focus for Teva will be to continue expanding in emerging markets.

"These are markets that are becoming increasingly sophisticated ... and it is very important for every company in the industry to understand how they will penetrate these markets," Levin said. "I do not think that this is something that should wait for the long term.

"I am very very interested and regard this as an important contributory leg to building a global company ... It is something I will be looking very carefully at."

(Reporting by Steven Scheer; Additional reporting by Lewis Krauskopf; Editing by Maureen Bavdek)

Source: http://us.rd.yahoo.com/dailynews/rss/health/*http%3A//news.yahoo.com/s/nm/20120103/hl_nm/us_teva

tebowing tebowing

Tuesday, January 3, 2012

Vikings CB Sapp cited for misdemeanor assault (AP)

MINNEAPOLIS ? Police say Minnesota Vikings cornerback Benny Sapp has been cited for fifth-degree assault and careless driving, both misdemeanors, after a run-in with security at Children's Hospital in Minneapolis.

Officers were called Friday morning after police say Sapp and his 11-year-old son tried to enter the hospital through a closed entrance. The Star Tribune reports Sapp left his son with a hospital security guard, saying the boy's mother was inside and he had to go to work.

Sapp allegedly pushed a security officer who tried to detain him in the parking ramp. Police Sgt. Bill Palmer says Sapp then chest-bumped a security officer who was standing in front of his vehicle.

A Vikings spokesman says the team is aware of the incident. Messages to Sapp's agent were not returned Saturday.

Source: http://us.rd.yahoo.com/dailynews/rss/sports/*http%3A//news.yahoo.com/s/ap/20120101/ap_on_sp_fo_ne/fbn_vikings_sapp_cited

duggar miscarriage dan gilbert david stern david stern julian beever

Thursday, December 29, 2011

Africa: Top Female Kenyan Scientist Reflects on Historic Research



allAfrica.com

Tabitha Mwangi

23 December 2011


At the Malaria Forum hosted by the Bill and Melinda Gates Foundation in October, the latest findings on what is currently the most viable malaria vaccine candidate in medical history, known as RTS,S, were announced.

Amidst the videotaping, camera flashes, Tweeting and blogging, Dr. Patricia Wamboi Njuguna awaited her turn at center stage at the Seattle forum. The only African woman in a team of 22 principal investigators on the Phase III trial of RTS,S, Njuguna couldn't give in to jet-lag after 24 hours of travel through five time zones. She couldn't afford to be nervous or hesitant. After all, she was representing not only the African scientists involved in this historic research, but all African scientists, of which women are a tiny minority.

And Njuguna also knew that after the pomp and ceremony of the Gates Foundation event, back home in Kenya, yet another a series of media interviews awaited her.

"It was such a hectic time. I spoke a lot more than I am used to," Njuguna recalls, laughing. "The best part of it all was the response of the community in Kilifi whose children were enrolled in the study. People were very excited by those findings."

And they should be. The October 18th announcement on the RTS,S vaccine candidate, produced by GlaxoSmithKline, found that it reduced the risk of clinical malaria by 56 percent, and severe malaria by 47 percent, in studies involving 6,000 children in 11 trial sites in Africa. The analysis was performed on data from children aged five to 17 months, during the 12 months after they received the vaccine.

Though researchers and global health officials quickly acknowledged that the data is just a milepost towards the ultimate goal of a licensed, effective vaccine, excitement about the data was palpable. The results were heralded in news outlets around the world, and many observers linked the research to the potential for many African nations to reach one of the United Nations Millennium Development Goals of reducing child mortality.

Njuguna, who headed the trial at the Kilifi, Kenya, site, spoke to AllAfrica.com about what sparked her interest in science and her role in the historic RTS,S project.

"My father was a plant breeder and director of the Kenya Agricultural Research Institute in Thika. We lived within the center and often got to see him at work on papaya and Valencia oranges," Njuguna said. "I always thought I would end up in agricultural research. But he advised me to try medicine instead."

So after high school at Bishop Gatimu Ngandu girls in Karatina, Njuguna joined the University of Nairobi for undergraduate medical training in 1992. During her fifth year, Njuguna spent six weeks at the KEMRI-Wellcome Trust Research Programme in Kilifi.

"I did a small project supervised by Professor Charles Newton, which was my very first exposure to clinical research," she said. "I found the process of research interesting, the exercise of attempting to answer scientific questions in this way, challenging."

In 1999, Njuguna completed her medical training and began an internship at the Coast Provincial General Hospital before returning to a medical posting at Kilifi District Hospital. Eventually, she applied for a medical research officer position at KEMRI-Wellcome Trust-Kilifi in 2001, the same year she married a fellow research scientist at the unit, Sam Kinyanjui, the current director of training and capacity building for KWT-Kilifi. The next three years were spent doing both clinical studies and working on larger research projects. One of those projects involved assessing children for neurological impairments and performing brain CT scans on a select few.

"As I was working with children all the time, I realized that I needed to have a good grasp of pediatrics. So I abandoned my dream of being a radiologist, which would have suited work/life balance as a woman, and went back to the University of Nairobi to pursue a Masters degree in pediatrics," Njuguna said.

"While I undertook my post-graduate training between 2003 and 2006, my husband was in the UK on a training fellowship conducting laboratory-based research in malaria immunology," she said. "We were both determined to acquire a certain level of training and expertise before starting a family. We wanted to be able to raise our children together."

When her training was finished, Njuguna was employed as a safety physician for the Phase II RTS,S malaria vaccine study. "I was in charge of surveillance for safety of study participants during this trial," she said. "Every ailment, whether it was perceived to be vaccine-related or not, was recorded so that an analysis would be conducted to determine the safety profile of the vaccine."

That Phase II trial, conducted between 2007 to 2008, was the landmark study were the RTS,S vaccine was shown to have a 53-percent protective effect against malaria. That meant the vaccine could qualify to proceed into the all-important Phase III trial stage, which would involve more children-and much higher stakes.

In 2009, Njuguna was asked to head the Phase III RTS,S malaria vaccine trial in Kilifi. "It was a daunting task, as double the number of children were recruited into the Phase III trial, compared to the trial we had just completed," Njuguna said. "We also had to set up different systems to run the trial. We have recruited 904 study participants, and to do this, 60 people are employed to work on the project. Training the varying teams was very labor intensive, especially since I also had my firstborn child around this time. However, once the teams were up and running, my work has been mainly managerial duties."

The research also yielded a massive investment in infrastructure. When the Phase II study was conducted in Junju and Pingilikani, the dispensary facilities were refurbished. With the Phase III trial, three new sites were selected: Ganze, Dida and Madamani. Government health facilities in these areas were extended and water tanks put in place, thanks to funding from the Malaria Clinical Trials Alliance. This funding also allowed for installation of a digital X-ray facility at the Kilifi District Hospital.

Although all these inputs are primarily for the study participants, the whole community and hospital benefits from their presence.

"Another benefit to the community is that we offer basic life support training to all the clinical staff in the health facilities were we work, a skill that will remain in the community long after we are gone," Njuguna said. "While the study is going on, we work very closely with staff at these facilities. We provide assistance with difficult cases, share drugs during stock-outs and assist in transport of services to the facility. We have ended up having a very good relationship with our study community, the staff at the health facilities and the district health management team."

In Kilifi, recruitment of children aged five to 17 months old was complete by August 2009 when the vaccinations began. Three doses were administered, and then data collected on the cases of clinical malaria among vaccinated children compared to those who were not. After a year, the data was analyzed and these were the results announced at the Malaria Forum.

By 2015, the global malaria research and public health community seems certain that the studies will yield a vaccine that will provide 50 percent protection against severe malaria. It will also be possible to tell whether the vaccine provides long-term protection as each child in the phase III trial will have been followed up for a period of at least 30 months.

The global public health community is also eagerly awaiting the results of the trials that recruited children six-12 weeks old for the three-dose RTS,S malaria vaccine. This data is the most precious, as it will yield information about whether the malaria vaccine can be used with maximum benefit in the EPI system.

But because the current vaccine candidate only gives about 50 percent protection at best, the scientific community is not resting. Malaria vaccine trials in Africa will continue until a vaccine with at least 80 percent efficacy is developed. GSK together with a company called Crucell are already working on creating a second-generation RTS,S vaccine that improves on the current vaccine. Even now, trials for other malaria vaccine candidates are underway on the continent.

In Kilifi, another colleague, Dr. Caroline Ogwang, has just completed data collection for a Phase I trial of a malaria vaccine candidate developed by a group at Oxford University. Through the African Malaria Network Trust (Amanet), another malaria vaccine candidate, GMZ-2 is undergoing Phase II field trials.

In the meantime, Njuguna may be over her jetlag, but her enthusiasm about the RTS,S is still going strong.

She said, "The road ahead is both challenging and exciting. So far collaborations within Africa are working very well and we have a lot to look forward to."

AllAfrica - All the Time



More News on allAfrica.com


Source: http://allafrica.com/stories/201112272824.html

uekman uekman music awards music awards giants eagles bcs rankings week 13 bcs rankings week 13